LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announced that it has entered into an automatic share purchase plan (the “ASPP”) with Eight Capital (the “Broker”) in order to facilitate repurchases of the…


Previous articleNature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
Next articleRevive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA